Skip to content
DataLookout
Menu

NCT04973605

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 58 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites reduced: 77 → 74 locations
  2. Notable Eligibility criteria expanded, about 14 words
    • Study sites: 78 to 77
    • Secondary endpoints: details revised at 1 of 11 entries
  3. Minor Trial sites reduced: 82 → 78 locationsv56
  4. Minor Study sites: 83 to 82v55
  5. Minor Study sites: 84 to 83v54
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Site details revised at 1 of 84 sitesv53
  2. Minor Site details revised at 2 of 84 sitesv52
  3. Minor Study sites: 83 to 84v51
  1. Minor Trial sites expanded: 80 → 83 locationsv50
  2. Minor Trial sites reduced: 83 → 80 locationsv49
  3. Minor Study sites revised (83)v48
  4. Minor Study sites: 84 to 83v47
  5. Minor Site details revised at 3 of 84 sitesv46
  6. Minor Site details revised at 1 of 84 sitesv45
  7. Minor Study sites: 85 to 84v44
  8. Minor Study sites: 86 to 85v43
  9. Minor Study sites: 88 to 86v42
  10. Notable Lead sponsor: BeiGene to BeOne Medicines
    • Study sites: 93 to 88
    v41
  11. Minor Study sites: 94 to 93v40
  12. Minor Site details revised at 2 of 94 sitesv39
  13. Minor Study sites: 89 to 94v38
  14. Minor Study sites: 88 to 89v37
  15. Minor Site details revised at 2 of 88 sitesv36
  16. Notable Eligibility criteria expanded, about 48 wordsv35 Show 4 more changesShow less
    • Primary endpoints revised (5)
    • Enrollment target: 167 to 246
    • Secondary endpoints revised (11)
    • Site details revised at 5 of 88 sites
  17. Minor Study sites: 89 to 88v34
  18. Minor Study sites: 88 to 89v33
  19. Minor Interventions: BGB-11417 (Drug), Carfilzomib (Drug), Dexamethasone (Drug) to Carfilzomib (Drug), Daratumumab (Drug), Dexamethasone (Drug), Pomalidomide (Drug), Sonrotoclax (Drug)v32
  20. Minor Site details revised at 1 of 88 sitesv31
  21. Minor Study sites: 32 to 88v30
  22. Minor Study sites: 77 to 32v29
  23. Minor Study sites: 70 to 77v28
  24. Minor Study sites: 71 to 70v27
  25. Minor Study sites: 69 to 71v26
  26. Minor Study sites: 64 to 69v25
  27. Minor Study sites revised (64)v24
  28. Minor Study sites: 61 to 64v23
  29. Minor Study sites: 56 to 61v22
  30. Minor Study sites: 49 to 56v21
  31. Minor Study sites: 42 to 49v20
  32. Minor Study sites: 27 to 42v19
  33. Minor Study sites revised (27)v18
  34. Minor Study sites: 24 to 27v17
  35. Minor Study sites: 23 to 24v16
  36. Minor Study sites: 74 to 23v15
  37. Minor Study sites: 24 to 74v13
  38. Notable Primary and study completion dates pushed to Nov 2026
    • Study sites revised (24)
    v12
  39. Minor Study sites: 22 to 24v11
  40. Minor Study sites: 21 to 22v10
  41. Minor Study sites: 6 to 21v9
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
Timeframe: Up to 28 days
Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events Leading to Discontinuation and Adverse Events of Special Interest (AESIs).
Timeframe: Up to 30 days after last dose of study drug
Part 2: Overall response rate (ORR) as Assessed by Investigator
Timeframe: Approximately 4 years
Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator
Timeframe: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]
Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator
Timeframe: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

Secondary (11)

Part 1: Area under the plasma concentration-time curve time 0 to the last measurable concentration (AUClast) After a Single Dose of Sonrotoclax
Part 1: Maximum observed plasma concentration (Cmax) After a Single Dose of Sonrotoclax
Part 1: Time to reach Cmax (tmax) After a Single Dose of Sonrotoclax
Part 1: At Steady-state: AUC last, ss
Part 1: At Steady-state: Cmax, ss
Show 6 moreShow less
Part 1: At Steady-state: trough plasma concentration (Ctrough) ss
Part 1: At Steady-state: time to reach Cmax (tmax,ss)
Part 2: Time to response (TTR) as Assessed by Investigator
Part 2: Duration of response (DOR) as Assessed by Investigator
Part 2: Progression-free survival (PFS) as Assessed by Investigator
Part 2: Overall survival (OS) as Assessed by Investigator

Arms and interventions

Part 1 Dose EscalationExperimental

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

Part 2 Cohort ExpansionExperimental

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

Drugs: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide

Sites

74 sites in 13 countries

China 21, United States 15, Brazil 7, Australia 6, Italy 5, South Korea 5, Germany 4, Canada 3, United Kingdom 3, Greece 2, France 1, Singapore 1, Spain 1